Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800011 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| Hydrochloric Acid SCHEMBL28797396 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| Hydrochloric Acid SCHEMBL28270652 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| SCHEMBL27862075 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| SCHEMBL13264880 | 0.85 | ALDH1A1 (0.46) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| Indole SCHEMBL27690415 | 0.85 | TRPA1 (0.47) | ALDH1A1KCNH2HSPA1APTPN7TDP1 | |
| SCHEMBL29892593 | 0.83 | KCNH2 (0.44) | ALDH1A1KCNH2PRMT5WDR77GAA | |
| SCHEMBL859610 | 0.83 | KCNH2 (0.44) | ALDH1A1KCNH2PRMT5WDR77GAA | |
| SCHEMBL30899479 | 0.81 | ALDH1A1 (0.54) | ALDH1A1F2 | |
| SCHEMBL768982 | 0.81 | ALDH1A1 (0.54) | ALDH1A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | claimed |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-26 | — | — | US | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2018371-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007136703-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1082305-A4 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1082305-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | claimed |
| JP-5255245-A | — | — | None | — | — | JP | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| JP-H05255245-A | 2,3-DIHYDROINDOLE-3,3-DICARBOXYLIC ACID AND 2,3-DIHYDROINDOLE-3-CARBOXYLIC ACID DERIVATIVE | KYORIN PHARMACEUT CO LTD | 1993-10-05 | — | — | JP | disclosed |
| EP-0480969-A4 | AMINO ACID ANALOG CCK ANTAGONISTS | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0480969-A1 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | ALDH1A1 3619/4885KCNH2 1717/4885HSPA1A 2406/4885 |
| US-20130345199-A1 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES | CXCR1, CXCR5, CXCR4 | ALDH1A1 1235/4885KCNH2 896/4885HSPA1A 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.